Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Outpatients~* Symptoms consistent with the diagnosis of asthma for at least 12 months~* Forced Expiratory Volume in one Second (FEV) at least 80% of predicted~* Participants who have a history of reversible airway obstruction~* Good health with the exception of asthma~Main Exclusion Criteria:~* History of life-threatening asthma~* A hospitalization for asthma within the last 3 months, or more than two hospitalizations for asthma within the last year~* Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids~* Participants suffering from relevant lung diseases causing alternating impairment in lung function (e.g. chronic bronchitis or emphysema)~* Prematurely born children (\<36 weeks of gestation)~* Smokers~* Pregnancy (or intention to become pregnant during the course of the trial), breast feeding or lack of safe contraception by female of child-bearing potential

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Ciclesonide 100 µg (Type: ACTIVE_COMPARATOR): Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
- Ciclesonide 200 µg (Type: ACTIVE_COMPARATOR): Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).